DK1601697T3 - Oprensning af antistof ved protein A- og ionbytningskromatografi - Google Patents

Oprensning af antistof ved protein A- og ionbytningskromatografi

Info

Publication number
DK1601697T3
DK1601697T3 DK04715906T DK04715906T DK1601697T3 DK 1601697 T3 DK1601697 T3 DK 1601697T3 DK 04715906 T DK04715906 T DK 04715906T DK 04715906 T DK04715906 T DK 04715906T DK 1601697 T3 DK1601697 T3 DK 1601697T3
Authority
DK
Denmark
Prior art keywords
antibody
purification
protein
ion exchange
exchange chromatography
Prior art date
Application number
DK04715906T
Other languages
English (en)
Inventor
Julian Bonnerjea
Anna Preneta
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32929391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1601697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0304576.2A external-priority patent/GB0304576D0/en
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Application granted granted Critical
Publication of DK1601697T3 publication Critical patent/DK1601697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
DK04715906T 2003-02-28 2004-03-01 Oprensning af antistof ved protein A- og ionbytningskromatografi DK1601697T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0304576.2A GB0304576D0 (en) 2003-02-28 2003-02-28 Protein a chromatography
US46497303P 2003-04-24 2003-04-24
PCT/EP2004/002041 WO2004076485A1 (en) 2003-02-28 2004-03-01 Antibody purification by protein a and ion exchange chromatography

Publications (1)

Publication Number Publication Date
DK1601697T3 true DK1601697T3 (da) 2007-10-01

Family

ID=32929391

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04715906T DK1601697T3 (da) 2003-02-28 2004-03-01 Oprensning af antistof ved protein A- og ionbytningskromatografi

Country Status (6)

Country Link
EP (1) EP1601697B1 (da)
AU (1) AU2004215653B2 (da)
CA (1) CA2516518A1 (da)
DK (1) DK1601697T3 (da)
PT (1) PT1601697E (da)
WO (1) WO2004076485A1 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
PT3095793T (pt) * 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005037869A2 (en) * 2003-10-15 2005-04-28 Applera Corporation Method of reducing leachate from protein a affinity media
PT1678208E (pt) 2003-10-27 2013-07-10 Wyeth Llc Remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatite
SE0400501D0 (sv) * 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
SE0402558D0 (sv) * 2004-10-21 2004-10-21 Amersham Biosciences Ab A process for the purification of antibodies
EP1685161A1 (en) * 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
WO2006043895A1 (en) * 2004-10-21 2006-04-27 Ge Healthcare Bio-Sciences Ab A method of antibody purification
AR054428A1 (es) * 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
WO2006099308A2 (en) 2005-03-11 2006-09-21 Wyeth A method of weak partitioning chromatography
CN1830495B (zh) * 2005-03-11 2010-12-15 广东天普生化医药股份有限公司 基于亲和吸附的血液净化方法及系统
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
ES2402650T3 (es) 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
FI2061803T4 (fi) * 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
RU2009148891A (ru) 2007-06-01 2011-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Очистка иммуноглобулина
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
US20110105725A1 (en) * 2008-05-15 2011-05-05 Novo Nordisk A/S Antibody purification process
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8058407B2 (en) 2008-10-31 2011-11-15 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
EP2360183B1 (en) 2008-12-19 2016-07-27 Takeda Pharmaceutical Company Limited Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
EP3037104B1 (en) 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
WO2011090719A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TW201326193A (zh) * 2011-11-21 2013-07-01 Genentech Inc 抗－ｃ－ｍｅｔ抗體之純化
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
RU2015122726A (ru) * 2012-11-15 2017-01-10 Дженентек, Инк. ОПОСРЕДОВАННАЯ ИОННОЙ СИЛОЙ рН-ГРАДИЕНТНАЯ ИОНООБМЕННАЯ ХРОМАТОГРАФИЯ
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
PL2986639T3 (pl) 2013-04-18 2022-01-10 Institut National De La Santé Et De La Recherche Médicale (Inserm) Kompozycja o zmniejszonej immunogenności
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
JP6293907B2 (ja) 2014-03-10 2018-03-14 リヒター ゲデオン エヌワイアールティー． プレクリーニング工程を用いた免疫グロブリンの精製
MA40232A (fr) 2014-06-13 2017-04-19 Lupin Ltd Procédé de purification de la protéine de fusion tnfr:fc
EP3613764A1 (en) 2014-10-15 2020-02-26 Xenothera Composition with reduced immunogenicity
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR101838645B1 (ko) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
WO2016103139A1 (en) * 2014-12-22 2016-06-30 Dr. Reddy's Laboratories Method for reduction of aggregates
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
AU2020266993A1 (en) 2019-04-30 2022-01-06 Xenothera Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer
EP4299756A4 (en) * 2021-03-09 2025-03-12 JCR Pharmaceuticals Co., Ltd. METHOD FOR PRODUCING AN ANTIBODY LYSOSOMALIC ENZYMFUSION PROTEIN
JP7719946B2 (ja) 2021-08-06 2025-08-06 エフ． ホフマン－ラ ロシュ アーゲー ＩｇＧアフィニティー精製のためのキメラＩｇＧ－Ｆｃ結合リガンドポリペプチド及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US4983722A (en) * 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
JPH07155194A (ja) * 1993-12-10 1995-06-20 Teijin Ltd タンパク質の精製法
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
SE9503925D0 (sv) * 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separationsmedium för IgG
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography

Also Published As

Publication number Publication date
AU2004215653B2 (en) 2011-03-17
AU2004215653A1 (en) 2004-09-10
WO2004076485A1 (en) 2004-09-10
EP1601697B1 (en) 2007-05-30
PT1601697E (pt) 2007-09-04
EP1601697A1 (en) 2005-12-07
CA2516518A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
DK1601697T3 (da) Oprensning af antistof ved protein A- og ionbytningskromatografi
DK3095793T3 (da) Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
DK1615955T3 (da) Ændring af FCRN-bindingsaffiniteter eller serumhalveringstider af antistoffer ved mutagenese
DK1543038T4 (da) Proteinoprensning
DK1599504T3 (da) Modificeret antistof
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
ECSP066436A (es) Compuestos heterociclicos fusionados
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1501856T3 (da) Anti-HER2 antistofvarianter
NO20044347L (no) Anti-alfavbeta6-antistoff
DK1545574T3 (da) Fremgangsmåde til rensning af polypeptider ved simuleret moving-bed-chromatografi
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
DK1647529T3 (da) Fremgangsmåde til oprensing af spildevand
CY2010016I2 (el) Αντισωματα σε μοριο προσδεσης της οστεοπροτεγερινης (opgl)
DK1273592T3 (da) Fremgangsmåde til oprensning af interferonproteiner ved hjælp af kationbytningskromatografi
DK1800693T3 (da) Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer
ATE500256T1 (de) Neue kondensierte pyrrolocarbazole
FI20010558L (fi) Kappaleiden paikannus
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
NO20054120D0 (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1527690T3 (da) Fremgangsmåde til dearomatisering af valleprotein
EP1598368A4 (en) ANTI-PCI neutralizing ANTIBODY
DK1377544T3 (da) Oprensning af 2-nitro-4-methylsulfonylbenzoesyre